By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioMarker Strategies 

606 Baltimore Avenue
Suite 402
Baltimore  Maryland  21204  U.S.A.
Phone: 410-532-2641 Fax: 410-532-6606


Company News
BioMarker Strategies Awarded Phase I NCI Contract To Develop Novel Predictive Test For Response To Immunotherapies For Patients With Non-Small Cell Lung Cancer 9/19/2016 11:11:25 AM
BioMarker Strategies Awarded Phase I/II Fast Track National Cancer Institute Grant To Develop Companion Diagnostic Test To Select Optimal Therapy For Patients With Non-Small Cell Lung Cancer 6/30/2016 9:25:22 AM
BioMarker Strategies Announces Issuance Of Key Patents In The United States, Europe, Australia And Hong Kong 1/7/2016 10:59:07 AM
BioMarker Strategies Names Jerry Parrott President and Chief Executive Officer 10/1/2013 10:44:41 AM
BioMarker Strategies Awarded $1.5 Million National Cancer Institute Contract to Develop Companion Diagnostic Test to Select Optimal Therapy for Melanoma Patients 9/25/2013 9:43:04 AM
BioMarker Strategies Names Jack Davis as Executive Chairman 10/3/2012 9:56:59 AM
BioMarker Strategies Appoints Glenn Miller to Board of Directors as Chairman 5/31/2011 9:30:18 AM
BioMarker Strategies Names Dr. Samuel Broder to Board of Directors 1/3/2011 9:37:42 AM
BioMarker Strategies Release: SnapPath(TM) Functional Signaling Profile Data Presented at San Antonio Breast Cancer Symposium 12/13/2010 9:10:38 AM
National Cancer Institute Awards $1 Million in SBIR Funding to BioMarker Strategies 5/3/2010 11:37:01 AM